Ad chides Gilead "greed" over Sovaldi pricing

Share this article:

The AIDS Healthcare Foundation (AHF) took out an ad in today's Wall Street Journal blasting Gilead and “our state and federal leaders,” whom the coalition charges with “breaking the bank by paying whatever Gilead and its pharma allies demand without question.”

The half-page, four-color ad was slated to run in WSJ editions in Northern California and the Washington/Maryland/Virginia markets, AHF said, coinciding with Gilead's Annual General Meeting in Millbrae, CA.

The headline of the ad reads:

 IF YOU THINK $1,000 A PILL IS OK STOP READING THIS.

The nonprofit AIDS organization has been a frequent critic of drug pricing and has been vocal before.

In January, the group's leader—Michael Weinstein—also referred to Gilead's HIV prevention treatment, Truvada, as a “party drug,” amid reports from the New York Times about the drug's stigma in the gay community.  

And in 2007 the group went so far as to file a suit with Pfizer over its DTC campaign for ED drug Viagra. AHF accused Pfizer of promoting recreational use of Viagra and suggested a link between the drug and illicit methamphetamine use. A Pfizer spokesperson at the time denied the claims and added that AHF had approached the company, “with a multimillion-dollar funding request for a crystal meth educational program.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.